Drugs / Tonabersat
Tonabersat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06437223 | Mar 2024 → Sep 2025 | long COVID-19 | Inflammx Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT00534560 | Oct 2007 → Nov 2008 | migraine with aura, migraine without aura | Minster Research Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00332007 | May 2006 → Aug 2008 | migraine with aura | Minster Research Ltd | Completed | Mixed |
| Phase 2 | NCT00311662 | Apr → Oct 2006 | migraine with aura, migraine without aura | Minster Research Ltd | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05727891 Comparator | May 2023 → Jun 2025 overdue | diabetic macular edema | Jaeb Center for Health Research | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tonabersat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00311662 ↗ |
| Known as | SB-220453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL318191 ↗ |
| Known as | Tonabersate | ChEMBL registry synonym — accepted as the source's own label CHEMBL318191 ↗ |
| Action | Inhibit | “Connexin43 hemichannel inhibitor” NCT05727891 ↗ |
| Modality | Small molecule | — CHEMBL318191 ↗ |
| Route | Oral | “Tablets” NCT00534560 ↗ |